<ref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barco</surname><given-names>S</given-names></name><name><surname>Voci</surname><given-names>D</given-names></name><name><surname>Held</surname><given-names>U</given-names></name><name><surname>Sebastian</surname><given-names>T</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Colucci</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial</article-title>. <source>Lancet Haematol</source>. (<year>2022</year>) <volume>9</volume>:<page-range>e585&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2352-3026(22)00175-2</pub-id>, PMID: <?supplied-pmid 35779558?><pub-id pub-id-type="pmid">35779558</pub-id>
</mixed-citation></ref>